Psychiatr. pro Praxi, 2007; 1: 9-12

Co ještě nevíme o bipolární poruše?

prof. MUDr. Eva Češková CSc
Psychiatrická klinika LF MU a FN Brno

With the advent of randomized clinical trials to prove efficacy for psychiatric treatment, it was necessary to devise methods to measure clinical outcomes and conceptualize remission also in bipolar disorder. At the beggining comorbidity and gender differences in course of the illness are discussed. Further this article details the pharmacotherapy. At first general recommendation for the treatment of bipolar disorder and criteria for individual choice are summarized. Recent views on treatment of mania, bipolar depression and maintenance treatment are reviewed. Finally the side effects problematic during maintenance treatment are mentioned. In near future answers for questions important in clinical practice should be found: What treatment is optimal for individual patient? What is the place of atypical antipsychotics in the treatment of bipolar disorder? How to resist the economic pressure and ensure availability of optimal known treatment for most of the patients?

Keywords: bipolar disorder, gender differences, mania, bipolar disorder, acute treatment, maintenance treatment

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Co ještě nevíme o bipolární poruše? Psychiatr. praxi. 2007;8(1):9-12.
Download citation

References

  1. Baldassano CF. Illness course, comorbidity, gender, and suicidality in patients with bipolar disorder. J Clin Psychiatry 2006; 67 (suppl 11): 8-11. Go to original source...
  2. Benazzi F. Mood patterns and classification in bipolar disorder. Current Opinions in Psychiatry 2006; 19: 1-8. Go to original source... Go to PubMed...
  3. Bowden CL, Calabrese JR, Sachs G et al. A placebo - controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400. Go to original source... Go to PubMed...
  4. Calabrese JR, Bowden ChL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024. Go to original source... Go to PubMed...
  5. Calabrese JR, Keck PE Jr, MacFadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-1360. Go to original source... Go to PubMed...
  6. Češková E, Kašpárek T. Léčba bipolární deprese. Čes a slov Psychiatrie 2004; 100: 229-237.
  7. Češková E. Léčba bipolární poruchy. Psychiatrie pro praxi 2005; 6: 172-178.
  8. Češková E. Novinky v léčbě bipolární deprese. Psychiatrie pro praxi 2006; 7: 128-130.
  9. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000; 61: 804-808. Go to original source... Go to PubMed...
  10. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press 1990; 1095 p.
  11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62. Go to original source... Go to PubMed...
  12. Hirschfeld RM, Hozer C, Calabrese JR et al. Validity of the Mood Disorder Questionnaire: a general population study. Am J Psychiatry 2003; 160: 178-180. Go to original source... Go to PubMed...
  13. Hirschfeld RM, Kasper S. A review of the evidence for carbamazepine and oxcarbazeine in the treatment of bipolar disorder. International J Neuropsychopharmacology 2004; 7: 507-522. Go to original source... Go to PubMed...
  14. Keck PE, McElroy SL, Tugrul KC, Bennett JA: Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993; 54: 305-308.
  15. Nierenberg AA, Ostacher MJ, Borrelli DJ et al. The integration of measurement and management for the treatment of bipolar disorder: a STEP-BD model of collaborative care in psychatry. J Clin Psychiatry 2006; 67 (suppl. 11): 3-7. Go to original source... Go to PubMed...
  16. Sachs GS. Implementing evidence-based treatment of manic and mixed episode. J Clin Psychiatry 2006; 67 (suppl. 11): 12-17.
  17. Suppes T, Dennehy EB, Hirchfeld RM, et al. The Texas Implementation of Medication Algorithms: Update to the Algorithms for Treatment of Bipolar I Disorder. J Clin Psychiatry 2005; 66: 870-886. Go to original source... Go to PubMed...
  18. Tohen M, Vieta E, Calabrese J, et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088. Go to original source... Go to PubMed...
  19. Vinař O. FKD rating scale. Activ Nerv Super 1966; 8: 409-411.
  20. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.